Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | BACE1 | P56817 | 10/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.34 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.34 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23705407 | 0.81 | MAPT (0.41) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL17802125 | 0.80 | MAPT (0.46) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL23704969 | 0.77 | RARA (0.49) | MAPTBLMAKR1B1MEN1KMT2A | |
| SCHEMBL30058908 | 0.77 | RARA (0.49) | MAPTBLMAKR1B1MEN1KMT2A | |
| SCHEMBL23704769 | 0.77 | RARA (0.49) | MAPTBLMAKR1B1MEN1KMT2A | |
| SCHEMBL23704772 | 0.77 | RARA (0.49) | MAPTBLMAKR1B1MEN1KMT2A | |
| SCHEMBL29790891 | 0.75 | MAPT (0.47) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL30749131 | 0.75 | MAPT (0.47) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL2599701 | 0.73 | RARA (0.48) | MAPTLMNAHTTBLMBACE1 | |
| SCHEMBL29616597 | 0.73 | RARA (0.48) | MAPTLMNAHTTBLMBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115484948-A | Compound and use thereof | 福宏治疗公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-4096657-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | MAPT 2074/4885LMNA 225/4885HTT 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.